Skip to main content

Serum chemerin level in chronic kidney disease

Abstract

Background

Chronic kidney disease (CKD) is a progressive loss in renal function over a period of months or years. In the metabolic association of an elevated circulating chemerin level in the context of uremia demonstrate that high chemerin levels predict a better survival in CKD patients. The aim of the study was to measure serum chemerin and to correlate it with other parameters in CKD patients.

Patients and methods

This study was conducted on 40 patients with CKD, including 20 patients with endstage renal disease under regular hemodialysis and 20 patients with renal impairment on conservative therapy who have not started hemodialysis, and 22 apparently healthy participants serving as the control group. Human chemerin is determined by sandwich enzyme immunoassay.

Results

There is a highly statistically significant difference in mean serum chemerin and mean serum high-sensitivity C-reactive protein (hs-CRP) in the patient groups in comparison with the control group. In addition, there was a highly statistically significant difference between control group, under hemodialysis group, and renal impairment group as regards serum chemerin and serum hs-CRP. A positive correlation between serum chemerin and hs-CRP studied in the under hemodialysis group, renal impairment group, and in all patients’ group.

Conclusion

A significantly higher chemerin level in patients with impaired kidney function compared with the normal control group, and a high increase in patients under hemodialysis compared with the other two groups.

References

  1. Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, et al. FGF23 inhibits extra-renal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res 2012; 28:46–55.

    Article  Google Scholar 

  2. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67:2089–2100.

    Article  Google Scholar 

  3. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137–147.

    Article  Google Scholar 

  4. Johnson D. CKD screening and management: overview [chapter 4]. In Daugirdas J. Handbook of chronic kidney disease management. Lippincott Williams & Wilkins; 2011. 32–43.

  5. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Investig 2006; 116:288–296.

    CAS  Article  Google Scholar 

  6. Sell H, Eckel J. Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation? Proc Nutr Soc 2009; 24:1–7.

    Google Scholar 

  7. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le poul E, Migeotte L, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003; 198:977–985.

    CAS  Article  Google Scholar 

  8. Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem J 2005; 280:34661–34666.

    CAS  Article  Google Scholar 

  9. Goralski KB, et al. Chemerin:a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007; 282:28175–28188.

    CAS  Article  Google Scholar 

  10. Cash JL, Hart R, Russ A, Dixon JPC. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med 2008; 205:767–775.

    CAS  Article  Google Scholar 

  11. Du XY, Zabel BA, Mylest T, Allen SJ, Handel T, Lee P, et al. Regulation of chemerin bioactivity by plasma corboxypeptidas n, corbox b (activated thrombin activable fibrinolysis inhibitor), and platelets. J Bio Chem 2009; 284:751–758.

    CAS  Article  Google Scholar 

  12. Yoshimura T, Oppenhein JJ. Chemerin reveals it chimeric nature. J Exp Med 2008; 205:2187–2190.

    CAS  Article  Google Scholar 

  13. Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitazawa R, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008; 582:573–578.

    CAS  Article  Google Scholar 

  14. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007; 148:4687–4694.

    CAS  Article  Google Scholar 

  15. Pfau D, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care 2009; 33:171–173.

    Article  Google Scholar 

  16. Friedwald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499.

    Article  Google Scholar 

  17. Perez-Fontan M, Cordido F, Rodriguez-Carmona A, Peteiro J, Garcia-Naveiro R, Garcia-Buela J. Plasma ghrelin in patients undergoing haemodialysis and peritoneal dialysis. Nephrol Dial Transplant 2004; 19:2095–2100.

    CAS  Article  Google Scholar 

  18. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Clinical Neph 2004; 27:1487–1495.

    Google Scholar 

  19. Grad E, Pachino RM, Fitzgerald GA, Danenberg HD. Role of thromboxane receptor in C-reactive protein-induced thrombosis. Arterioscler Thromb Vasc Biol 2012; 32:2468–2474.

    CAS  Article  Google Scholar 

  20. Chu SH, Lee MK, Ahnk Y, Im JA, Park MS, Lee DC, et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PloS One 2012; 7:e34710.

  21. Dorte P, Anette B, Matthias B, Micheal S, Jurgen K. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care 2012; 33:171–173.

    Google Scholar 

  22. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007; 18:293–303.

    CAS  Article  Google Scholar 

  23. Adlar AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63:225–232.

    Article  Google Scholar 

  24. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L. A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73:391–398.

    CAS  Article  Google Scholar 

  25. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity–related insulin resistance. J Clin Invest 2003; 112:1821–1830.

    CAS  Article  Google Scholar 

  26. Lehrke M, Becker A, Greif M, Stark R, Laubender RP, Von Ziegler F, Lebherz C, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009; 161:339–344.

    CAS  Article  Google Scholar 

  27. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol 2010; 395:106–110.

    Google Scholar 

  28. Ikizler TA. Resolved: being fat is good for dialysis patients: the Godzilla effect: pro. J Am Soc Nephrol 2008; 19:1059–1062.

    Article  Google Scholar 

  29. Axelsson J, Rashid Qureshi A, Suliman ME, Honda H, Pecoits-Filho R, Heimburger O, et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004; 80:1222–1229.

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Naglaa Abd Elfattah Tawfik PhD.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work noncommercially, as long as the author is credited and the new creations are licensed under the identical terms

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Abd Rabo, S.A.E., Mohamed, N.A.G., Tawfik, N.A.E. et al. Serum chemerin level in chronic kidney disease. Egypt J Intern Med 28, 99–107 (2016). https://doi.org/10.4103/1110-7782.200964

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/1110-7782.200964

Keywords

  • chemerin
  • chronic kidney disease
  • high-sensitivity C-reactive protein
  • insulin